摘要
目的探讨细胞因子诱导的杀伤细胞(CIK)免疫治疗联合肝动脉化疗栓塞(TACE)术治疗原发性肝癌患者的临床疗效。方法选择2012年2月~2014年2月间在本院确诊并行TACE术的67例原发性肝癌患者,按是否联合CIK治疗分为联合治疗组(CIK+TACE)32例和对照组(TACE)35例,比较两组患者外周血T淋巴细胞亚群变化、生活质量(QOL)改善、临床疗效、无进展生存期(PFS)等指标。结果在CIK首次回输后7 d,联合治疗组患者外周血CD3^+、CD4^+细胞的比例和CD4^+/CD8^+比值分别为(70.32±2.36)%、(32.18±2.27)%和(1.15±0.05),显著高于CIK细胞治疗前水平[(63.56±2.42)%、(30.34±2.05)%和(0.90±0.05),P<0.05)];CIK细胞治疗后外周血CD8+细胞比例为(29.35±2.95)%,显著低于治疗前水平[(33.28±3.14)%,P<0.05];联合治疗组患者生活质量明显改善,治疗前后Karuafsky评分分别为(74.6.±12.5)和[(83.4±14.7),P<0.05];联合治疗组部分缓解率为53.1%,与对照组42.9%比,无显著性差异(P>0.05);联合治疗组中位PFS为16个月,显著高于对照组的9.5个月(P<0.05);CIK治疗后不良反应轻微,对症处理后均恢复正常。结论 CIK细胞免疫疗法联合TACE术较单纯TACE术治疗,可以提高肝癌患者的细胞免疫功能,改善原发性肝癌患者的生存质量,延缓肿瘤进展。
Objective To investigate the clinical efficacy of cytokine-induced killer cells （CIK） combined with transcatheter arterial chemoembolization （TACE） for patients with primary liver cancer. Methods A total of 67 patients with primary liver cancer were enrolled in Daping hospital from February 2012 to February 2014. According to therapy choice,the patients were divided into combination treatment group （n=32,treated with CIK plus TACE） and control group （n=35,treated with TACE alone）. The peripheral T-lymphocyte subsets alterations, quality of life （QOL）,clinical efficacy and the progression-free-survival （PFS） after treatment were compared between the two groups. Results The proportions of CD3cr lymphocytes,CD4CF lymphocytes and CD4＋/CD8＋ ratio in peripheral blood were significantly increased 7 days after CIK treatment in combination therapy group [（70.32± 2.36）% vs.（63.56±2.42）%,（32.18±2.27）% vs.（30.34±2.05）%,and（1.15±0.05） vs.（0.90±0.05）, respectively,P〈0.05 for all];The proportion of CD8±T lymphocytes was significantly decreased in combination treatment group [（29.35± 2.95）% vs.（33.28±3.14）%,P〈0.05];Partial remission rate was higher in combination treatment group as compared with that in control group,hut with no statistical difference （53.1% vs. 42.9% ,P〉0.05 ）;The median PFS was significantly different between the two groups （16 months vs. 9.5 months,P〈0.05）;Adverse effects in combination treatment group were haild,and the symptoms disappeared after managements. Conclusions CIK combined with TACE therapy can significantly inerease the cell immune function in patients with primary liver cancer than TACE therapy alone, it can improve the QOL and slow the progress of liver cancer in patients with hepatocellular carcinoma.
出处
《实用肝脏病杂志》
CAS
2015年第6期647-650,共4页
Journal of Practical Hepatology
关键词
原发性肝癌
肝动脉化疗栓塞
细胞因子诱导的杀伤细胞
治疗
Primary liver cancer
Transcatheter arterial chemoembolization
Cytokine-induced killer cells
Therapy
